Download App
PAPER TRADE
Download App
Login
Home
>
Pharmaceuticals and health care Stocks
>
JAGSNPHARM
Overview
Tech Summary
Promoter Holding
Posts
J
JAGSNPHARM
4
0
1
2
3
4
5
6
7
8
9
1
0
1
2
3
4
5
6
7
8
9
2
0
1
2
3
4
5
6
7
8
9
.
3
0
1
2
3
4
5
6
7
8
9
0
0
1
2
3
4
5
6
7
8
9
-0.75 (-0.18%)
The current prices are delayed.
Login/Sign Up
to see live prices.
Previous Close: 413.05
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
408.65
Today's high
417.65
52 week low
285
52 week high
514.85
Volume
12825
About
TECHNICAL SUMMARY
DMA(12)
₹287.15
DMA(50)
₹300.9
DMA(100)
₹267.31
DMA(200)
₹214.45
FUNDEMANTAL SUMMARY
Market Cap
₹1080.23 Cr.
Enterprise Value
₹965.6 Cr.
No. of Shares
2.62
P/E
34.53
RoE
18.89
Debt/Equity
Valuations
PE CHART
30
40
50
60
70
PB CHART
5.0
5.5
6.0
6.5
7.0
7.5
Promoter Holdings
Public : 30.08%
FII : 0.37%
DII : 0.83%
Promoter : 68.71%
Others : 0%
PEER COMPARISON
Peer companies
SUNPHARMA
SOLARA
NGLFINE
VIMTALABS
JAGSNPHARM
KOPRAN
SMSPHARMA
Market Capital (Cr.)
269693.32
1269.36
1240.78
1211.96
1080.23
1076.55
1039.69
P/E
254.53
-55.4
45.14
25.9
34.53
39.01
44.84
P/B
11.18
0.86
5.3
4.25
6.85
2.72
2.06
Price(₹)
1132.35
350.3
2006.85
539.1
413.05
222.7
122.2
Charts
❮
❯
DEBT/EQUITY
0.000
0.010
0.020
0.030
0.040
0.050
0.060
Mar, 2019
Mar, 2020
Mar, 2021
Mar, 2022
Mar, 2023
ROE VS ROCE
10
15
20
25
Mar, 2019
Mar, 2020
Mar, 2021
Mar, 2022
Mar, 2023
ROE
ROCE
REVENUE VS PROFITABILITY (1000CR.)
0.05
0.10
0.15
0.20
0.25
Mar, 2019
Mar, 2020
Mar, 2021
Mar, 2022
Mar, 2023
Revenue
Profit
MARGINS(%)
4
6
8
10
12
14
16
18
Mar, 2019
Mar, 2020
Mar, 2021
Mar, 2022
Mar, 2023
Net Margin
Gross Margin
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Login / Sign up
Stock Sentiments
100% Bullish
0% Bearish
14 live trades of
Rs. 1,804,894.4
2
22446688
Reputation: 0 •
Sep 22 7:02 PM
JAGSNPHARM
500 Qty (S) Trade entered
-₹325
2
22446688
Reputation: 0 •
Sep 22 7:01 PM
JAGSNPHARM
500 Qty (S) Exited
₹0
Posts by FrontPage Users
list
This list is empty..
Cheer up, all is well :)
Load More Posts